BACKGROUND: The Centers for Medicare and Medicaid Services provides public reporting on the quality of hospital care for patients with acute myocardial infarction (AMI). The Centers for Medicare and Medicaid Services Core Measures allow discretion in excluding patients because of relative contraindications to aspirin, β-blockers, and angiotensin-converting enzyme inhibitors. We describe trends in the proportion of patients with AMI with contraindications that could lead to discretionary exclusion from public reporting. METHODS: We completed cross-sectional analyses of 3 nationally representative data cohorts of AMI admissions among Medicare patients in 1994-1995 (n = 170,928), 1998-1999 (n = 27,432), and 2000-2001 (n = 27,300) from the national Medicare quality improvement projects. Patients were categorized as ineligible (eg, transfer patients), automatically excluded (specified absolute medical contraindications), discretionarily excluded (potentially excluded based on relative contraindications), or "ideal" for treatment for each measure. RESULTS: For 4 of 5 measures, the percentage of discretionarily excluded patients increased over the 3 periods (admission aspirin 15.8% to 16.9%, admission β-blocker 14.3% to 18.3%, discharge aspirin 10.3% to 12.3%, and angiotensin-converting enzyme inhibitors 2.8% to 3.9%; P < .001). Of patients potentially included in measures (those who were not ineligible or automatically excluded), the discretionarily excluded represented 25.5% to 69.2% in 2000-2001. Treatment rates among patients with discretionary exclusions also increased for 4 of 5 measures (all except angiotensin-converting enzyme inhibitors). CONCLUSIONS: A sizeable and growing proportion of patients with AMI have relative contraindications to treatments that may result in discretionary exclusion from publicly reported quality measures. These patients represent a large population for which there is insufficient evidence as to whether measure exclusion or inclusion and treatment represents best care.
BACKGROUND: The Centers for Medicare and Medicaid Services provides public reporting on the quality of hospital care for patients with acute myocardial infarction (AMI). The Centers for Medicare and Medicaid Services Core Measures allow discretion in excluding patients because of relative contraindications to aspirin, β-blockers, and angiotensin-converting enzyme inhibitors. We describe trends in the proportion of patients with AMI with contraindications that could lead to discretionary exclusion from public reporting. METHODS: We completed cross-sectional analyses of 3 nationally representative data cohorts of AMI admissions among Medicare patients in 1994-1995 (n = 170,928), 1998-1999 (n = 27,432), and 2000-2001 (n = 27,300) from the national Medicare quality improvement projects. Patients were categorized as ineligible (eg, transfer patients), automatically excluded (specified absolute medical contraindications), discretionarily excluded (potentially excluded based on relative contraindications), or "ideal" for treatment for each measure. RESULTS: For 4 of 5 measures, the percentage of discretionarily excluded patients increased over the 3 periods (admission aspirin 15.8% to 16.9%, admission β-blocker 14.3% to 18.3%, discharge aspirin 10.3% to 12.3%, and angiotensin-converting enzyme inhibitors 2.8% to 3.9%; P < .001). Of patients potentially included in measures (those who were not ineligible or automatically excluded), the discretionarily excluded represented 25.5% to 69.2% in 2000-2001. Treatment rates among patients with discretionary exclusions also increased for 4 of 5 measures (all except angiotensin-converting enzyme inhibitors). CONCLUSIONS: A sizeable and growing proportion of patients with AMI have relative contraindications to treatments that may result in discretionary exclusion from publicly reported quality measures. These patients represent a large population for which there is insufficient evidence as to whether measure exclusion or inclusion and treatment represents best care.
Authors: Dale R Burwen; Deron H Galusha; Jennifer M Lewis; Marjorie R Bedinger; Martha J Radford; Harlan M Krumholz; JoAnne Micale Foody Journal: Arch Intern Med Date: 2003-06-23
Authors: Peter K Lindenauer; Denise Remus; Sheila Roman; Michael B Rothberg; Evan M Benjamin; Allen Ma; Dale W Bratzler Journal: N Engl J Med Date: 2007-01-26 Impact factor: 91.245
Authors: T A Marciniak; E F Ellerbeck; M J Radford; T F Kresowik; J A Gold; H M Krumholz; C I Kiefe; R M Allman; R A Vogel; S F Jencks Journal: JAMA Date: 1998-05-06 Impact factor: 56.272
Authors: S F Jencks; T Cuerdon; D R Burwen; B Fleming; P M Houck; A E Kussmaul; D S Nilasena; D L Ordin; D R Arday Journal: JAMA Date: 2000-10-04 Impact factor: 56.272
Authors: H M Krumholz; M J Radford; E F Ellerbeck; J Hennen; T P Meehan; M Petrillo; Y Wang; T F Kresowik; S F Jencks Journal: Circulation Date: 1995-11-15 Impact factor: 29.690
Authors: E F Ellerbeck; S F Jencks; M J Radford; T F Kresowik; A S Craig; J A Gold; H M Krumholz; R A Vogel Journal: JAMA Date: 1995-05-17 Impact factor: 56.272
Authors: Ian J Barbash; Hongwei Zhang; Derek C Angus; Steven E Reis; Chung-Chou H Chang; Francis R Pike; Jeremy M Kahn Journal: Med Care Date: 2017-05 Impact factor: 2.983
Authors: Mihaela S Stefan; Penelope S Pekow; Wato Nsa; Aruna Priya; Lauren E Miller; Dale W Bratzler; Michael B Rothberg; Robert J Goldberg; Kristie Baus; Peter K Lindenauer Journal: J Gen Intern Med Date: 2012-10-16 Impact factor: 5.128
Authors: Cecilia Berardi; Alanna M Chamberlain; Francesca Bursi; Margaret M Redfield; Sheila M McNallan; Susan A Weston; Ruoxiang Jiang; Véronique L Roger Journal: Am Heart J Date: 2013-05-08 Impact factor: 4.749
Authors: Daniel E Forman; Mathew S Maurer; Cynthia Boyd; Ralph Brindis; Marcel E Salive; Frances McFarland Horne; Susan P Bell; Terry Fulmer; David B Reuben; Susan Zieman; Michael W Rich Journal: J Am Coll Cardiol Date: 2018-05-15 Impact factor: 24.094
Authors: Akshay Pendyal; Craig Rothenberg; Jean E Scofi; Harlan M Krumholz; Basmah Safdar; Rachel P Dreyer; Arjun K Venkatesh Journal: J Am Heart Assoc Date: 2020-10-13 Impact factor: 5.501